The term acute myeloid leukemia (AML) collectively refers to a mixture of distinct diseases
that differ with regard to their pathogenetic evolution, genetic abnormalities, clinical features …

Acute myeloid leukemia (AML) is characterized as a heterogeneous disease where the
patients are sub grouped according to several classification systems and mutational …

BACKGROUND AND OBJECTIVE: The successful use of differentiating treatment for
patients with acute promyelocytic leukemia (APL) suggests that other acute myeloid …

Genetic and molecular techniques have provided increasing insights into the biology of
acute myeloid leukemia (AML). These investigations showed that AML is not a …

The heterogeneity of acute myeloid leukemia (AML) results from a complex network of
cytogenetic aberrations and molecular mutations. These genetic markers are the basis for …

Abstract In this chapter, Drs. Keating and Willman review recent advances in our
understanding of the pathophysiology of acute myeloid leukemia (AML) and allied …

Although standard therapy for AML has been relatively constant over the past 2 decades,
this may be changing with enhanced technologies allowing for the classification of acute …

Today, treatment of patients with acute myeloid leukemia (AML) remains predominantly a
“one-fits-all” approach with intensive cytarabine-based chemotherapy as the mainstay, but …

Over the last decades, significant advances have been made in the knowledge and
treatment of acute myeloid leukemia (AML). The WHO has recognized this new information …

Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically
heterogeneous disease, and its incidence is increasing as the population ages …